The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
Emre Yekedüz, Deniz Tural, İsmail Ertürk, Serdar Karakaya, Cihan Erol, Özlem Erçelep, Çağatay Arslan, Özlem Nuray Sever, Saadettin Kılıçkap, Nihan Şentürk Öztaş, Ahmet Küçükarda, Orçun Can, Berna Öksüzoğlu, Mehmet Alı Nahıt Şendur, Nuri Karadurmuş, Yüksel Ürün
Topics & Concepts
MedicineNivolumabRenal cell carcinomaInternal medicineOncologyCancerKidney cancerNephrologyBiomarkerHematologyNeutrophil to lymphocyte ratioGastroenterologyImmunotherapyLymphocyteChemistryBiochemistryInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis